"The investigational monoclonal antibody BIIB033 (Biogen) appears not only to improve optic nerve latency in the affected eye of patients with acute optic neuritis (AON), often one of the first manifestations of multiple sclerosis (MS), but also h"...
Betaxon Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Betaxon (levobetaxolol hydrochloride) Ophthalmic Suspension 0.5% is a beta-blocker used to treat glaucoma or increased pressure in the eye. The brand name of this medication is discontinued, but generic versions may be available. Common side effects include eye burning or stinging, blurred vision, anxiety, dizziness, or upset stomach.
The recommended dose is one drop of Betaxon 0.5% in the affected eye(s) twice daily. Betaxon may interact with other eye medications, other beta-blockers, reserpine, prazosin, doxazosin, tamsulosin, terazosin, or stimulant drugs. Tell your doctor all medications and supplements you use. It is unknown if Betaxon will be harmful to a fetus. Tell your doctor if you are pregnant or could become pregnant during treatment. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Betaxon (levobetaxolol hydrochloride) Ophthalmic Suspension 0.5% Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Betaxon FDA Prescribing Information: Side Effects
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Ocular: In clinical trials, the most frequent event associated with the use of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension 0.5% has been transient ocular discomfort upon instillation (11%). Transient blurred vision has been reported in approximately 2% of patients. Other ocular events have been reported in less than 2% of patients and include: cataracts, and vitreous disorders.
Systemic: Systemic reactions following administration of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension 0.5% and other topical ocular formations of betaxolol have been at an incidence of less than 2%. These include:
Digestive: Constipation and dyspepsia.
Musculoskeletal: Arthritis and tendonitis.
Other: Accidental injury, headache, and infection.
In a three-month, multi-center, double-masked, active-controlled trial in pediatric patients, the adverse event profile of BETAXON™ (levobetaxolol hydrochloride ophthalmic suspension) Ophthalmic Suspension was comparable to that seen in adult and elderly patients.
Read the entire FDA prescribing information for Betaxon (Levobetaxolol Hydrochloride Ophthalmic Suspension)
Additional Betaxon Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.